**Bottom Line**
If the question is strictly the gap, the only decisive experiment is **adult, neuron-specific AMPK restoration after microglial inflammation is already established**. That is the best **biology test**. It is not the best **drug-development program**.
For translational feasibility, the ideas that still survive are:
1. **H1 neuronal AMPK restoration** as a causal validation study, not a near-term therapeutic platform.
2. **H7 NLRP3 inhibition** as the most druggable downstream reversal strategy.
3. **H2 FABP-axis interruption** as a plausible but still under-validated second-line translational bet.
I would drop **H4 LXR**, **H5 PDH/DCA**, and **H6 lactate-shuttle rescue** for development prioritization. **H3 ULK1/autophagy** is mechanistically interesting but too under-specified and too hard to de-risk as a drug program right now.
**Best-surviving ideas**
**1. H1: Restore neuronal AMPK activity**
This is the highest-value experiment for answering the gap because it directly tests reversibility. The key correction is that the experiment must be **post-onset rescue**, not pre-symptomatic prevention. Use an inducible neuronal system in adult animals with documented microglial activation already present, then ask whether restoring AMPK normalizes microglial state.
Druggability is the main problem. AMPK is druggable in a broad sense, but **neuron-selective CNS restoration** is not a mature modality. Small-molecule AMPK activators are unlikely to give clean neuron-specific target engagement, and gene therapy raises delivery, durability, and regulatory complexity. So this is a **target-validation program**, not a realistic first therapeutic candidate.
Best biomarkers:
- CSF/plasma neuroinflammation: sTREM2, YKL-40, GFAP, possibly cytokine panels
- Tissue: microglial DAM markers (`Trem2`, `Itgax`, `Clec7a`), Iba1/TMEM119 morphology
- Mechanistic: brain lipidomics, MALDI imaging, neuronal lipid droplet burden, p-ACC as AMPK pathway readout
Best models:
- Adult inducible neuronal AMPK loss/rescue model is stronger than constitutive KO
- Add a disease background only after the core rescue effect is shown
- Human iPSC neuron-microglia co-cultures are useful for mechanism, not enough for reversal proof alone
Safety:
- Too much AMPK activation risks synaptic/metabolic stress
- AAV-based rescue adds standard CNS gene therapy risk and long timelines
Realistic timeline/cost:
- Mouse causal package: roughly **18–24 months**, **$1.5M–$3M**
- Therapeutic path from there: materially longer; likely **5+ years** before credible IND-oriented positioning
**2. H7: NLRP3 inhibition**
This is the most clinically actionable surviving idea. It does not prove neuronal AMPK reversibility, but it directly tests whether the inflammatory arm is still pharmacologically reversible once the circuit is engaged. If the goal shifts from target validation to treatment feasibility, this is the cleanest path.
Druggability is strong relative to the rest. NLRP3 is a recognized inflammatory target class with tractable medicinal chemistry and translational logic. The main caveat is mechanism: success here would show that downstream inflammation is reversible, not that neuronal AMPK itself is the optimal drug target.
Best biomarkers:
- CSF IL-1β / IL-18 if measurable
- Microglial PET where available, though not pathway-specific
- Brain ASC specks, caspase-1 activation, inflammasome transcriptional signatures
- Standard neurodegeneration context markers: NfL, GFAP, sTREM2
Best models:
- Same adult post-onset model
- Strongest design is head-to-head against neuronal AMPK rescue to see whether inflammation improves without correcting the upstream lipid phenotype
Clinical constraints:
- Need CNS exposure and chronic dosing feasibility
- Must show benefit beyond generic anti-inflammatory suppression
Safety:
- Chronic innate immune suppression and infection risk are the main concerns
- Peripheral immunology liabilities are more manageable than LXR metabolic toxicity
Realistic timeline/cost:
- Preclinical reversal package: **12–18 months**, **$1M–$2M**
- If using a development-ready scaffold, this is the fastest path to translational relevance
**3. H2: FABP inhibition**
This survives as a mechanistically plausible “middle-of-pathway” intervention. It is more targetable than neuronal AMPK restoration and more pathway-proximal than NLRP3, but the biology is less secure. Redundancy, cell-type ambiguity, and uncertain CNS selectivity are real risks.
Druggability is moderate. Small molecules exist, but isoform selectivity, brain penetration, and interpretation are all nontrivial. This is a good **mechanism-deconvolution** program and a possible therapeutic hedge, not the lead program.
Best biomarkers:
- Brain and CSF lipid species linked to the transfer pathway
- Microglial inflammatory markers plus lipid droplet burden
- Target-engagement markers will need bespoke assay work
Best models:
- Cell-type-specific knockouts are critical
- Co-culture and organoid systems are especially useful here because the intercellular transfer question is central
Safety:
- Broad FABP inhibition can hit multiple glial and peripheral compartments
- Long-term CNS lipid-handling perturbation could create off-target neurobiology
Realistic timeline/cost:
- Good de-risking package: **18–24 months**, **$1.5M–$3M**
- Higher probability of attrition than NLRP3
**Ideas I would deprioritize**
- **H3 ULK1/autophagy**: interesting biology, weak construct logic, poor selectivity, hard safety window.
- **H4 LXR agonism**: systemic lipid toxicity and isoform nonselectivity are major liabilities.
- **H5 DCA/PDH**: too indirect, weak CNS pharmacology for the stated purpose.
- **H6 astrocyte-neuron lactate shuttle**: biologically diffuse and too far from a development-ready intervention.
**Recommended decision tree**
1. Run the decisive experiment: **adult neuronal AMPK rescue after inflammation is established**.
2. In parallel, run **NLRP3 inhibition** as the translational benchmark.
3. If AMPK rescue works and NLRP3 only partially works, the pathway is probably upstream-lipid dependent and worth pushing toward H2/H3-style mechanistic refinement.
4. If NLRP3 works but AMPK rescue does not, AMPK is more likely a disease-state marker/modulator than a viable reversal target.
**Practical portfolio ranking**
- **Best for answering the gap:** H1
- **Best therapeutic tractability:** H7
- **Best pathway-proximal backup:** H2
If you want, I can turn this into a scored diligence table with `feasibility / druggability / biomarker readiness / safety / cost` columns for all seven hypotheses.